System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Tsvetalina Tankova is an expert in Endocrinology at Medical University of Sofia (Bulgaria). As of October 2026, ScienceLeadR ranks Tsvetalina Tankova in the top 1% of experts worldwide for Glucose Metabolism Disorders and Diabetes Mellitus. Tsvetalina Tankova has authored 181 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 3 of them ongoing. SLR score: 687 (community average: 125). How the SLR is computed.

LeadR Profile

Tsvetalina Tankova Medical University of Sofia Bulgaria
687 ScienceLeadR Reputation 687

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Pediatrics - Nutrition - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Medical University of Sofia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 181

Citations

Citations: 17 822 1st author: 15 Last author: 36 Unique author: 1

Main journals

Diabetes Res Clin Pract 16
Diabetes Care 9
BMC Endocr Disord 8
Diabetes 7
Diabetes Ther 7

Best Journals

N Engl J Med 5
Lancet Diabetes Endocrinol 2
Nat Rev Dis Primers 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Who Benefited Most? Identifying Parent-Child Dyads With Improved Weight Outcomes in the Feel4Diabetes Study.
PMID 42827214 — pediatric obesity, obesity, child		Pediatr Obes20260
Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
PMID 42825923 — diabetes mellitus, glucagon-like peptide 1, therapeutics, diabetes mellitus, type 2		Diabetologia20261
Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
PMID 42825450 — diabetes mellitus, glucagon-like peptide 1, therapeutics, diabetes mellitus, type 2		Diabetes Care20260
The temporal relationship among socioeconomic vulnerability, dietary intake, and childhood obesity across six European countries: longitudinal results from the Feel4Diabetes-study.
PMID 42747589 — pediatric obesity, feeding behavior, public health, diet, obesity, pediatrics, child, dietary patterns		Eur J Pediatr20260
Beyond the CE Mark: A Call to Action for Minimum CGM Accuracy Standards in Central and Eastern European Nations.
PMID 42736033 — diabetes mellitus, type 1		Diabetes Obes Metab20260

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 12
Phase 2 3
N/A 1
Phase 4 1

By status:

Completed 11
Active not recruiting 2
Terminated 2
Recruiting 1
Unknown 1

By type:

Interventional 17

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 13

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A research study to see how well CagriSema helps people with excess body weight lose weight
2023-506929-11-00 — safety, body weight, obesity, research, overweight, semaglutide		Phase 3Active not recruiting2022
A research study comparing how well different doses of the medicine NNC0519 0130 can reduce kidney damage in people living with chronic kidney disease
2024-510846-15-00 — diabetes mellitus, kidney diseases, safety, kidney, obesity, research, overweight, pharmacokinetics, diabetes mellitus, type 2, semaglutide		Phase 2Active not recruiting2025
AMAZE 8 A research study investigating how well the medicine NNC0487 0111 compared to semaglutide helps people with excess body weight and type 2 diabetes lose weight
2024-520446-31-00 — diabetes mellitus, safety, body weight, obesity, research, overweight, diabetes mellitus, type 2, semaglutide		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS